To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

NCT01900249 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Keratoconjunctivitis Sicca

Interventions

DRUG: R348 Ophthalmic Solution, 0.2%
DRUG: R348 Ophthalmic Solution, 0.5%
DRUG: Placebo

Sponsor

Rigel Pharmaceuticals